Shares of SenesTech Inc (NASDAQ:SNES) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price objective of $2.50 for the company and are anticipating that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 106 out of 255 based on the ratings given to related companies.
Separately, Zacks Investment Research raised SenesTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 30th.
SenesTech (NASDAQ:SNES) last released its quarterly earnings data on Monday, August 13th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.40 million. SenesTech had a negative net margin of 13,362.22% and a negative return on equity of 214.75%. On average, equities research analysts expect that SenesTech will post -0.61 EPS for the current fiscal year.
An institutional investor recently bought a new position in SenesTech stock. Bank of Montreal Can acquired a new stake in SenesTech Inc (NASDAQ:SNES) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 80,000 shares of the company’s stock, valued at approximately $131,000. Bank of Montreal Can owned approximately 0.48% of SenesTech at the end of the most recent reporting period. Institutional investors and hedge funds own 8.03% of the company’s stock.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Featured Story: What is the float in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.